Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid
Authors:
- Christiane RordorfCRChristiane Rordorf
- Dennis A RuffDRDennis A Ruff
- 1 January 2004
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 43 (7) , 467-478
Abstract
Background umiracoxib is a new cyclo-oxygenase-2 (COX-2) selective inhibitor in development for the treatment of rheumatoid arthritis, osteoarthritis and acute pain.Keywords
This publication has 28 references indexed in Scilit:
- World Medical Association Declaration of HelsinkiJAMA, 2000
- Articular Diffusion of Meloxicam After a Single Oral DoseClinical Pharmacokinetics, 2000
- Pharmacokinetics of Nonsteroidal Anti-Inflammatory Drugs in Synovial FluidClinical Pharmacokinetics, 1999
- Clinical Pharmacokinetics of TenoxicamClinical Pharmacokinetics, 1994
- Stereoselective Disposition of Etodolac Enantiomers in Synovial FluidThe Journal of Clinical Pharmacology, 1991
- Recent Findings on the Pharmacokinetics of Non-Steroidal Anti-Inflammatory Drugs in Synovial FluidClinical Pharmacokinetics, 1989
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Synovial Fluid and Plasma Kinetics of Repeat Dose Sustained Action Tiaprofenic Acid in Patients with Rheumatoid ArthritisDrugs, 1988
- Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritisEuropean Journal of Clinical Pharmacology, 1983
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981